Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AmpliPhi Biosciences has terminated its collaboration agreement with Intrexon which was signed in 2013 to develop new bacteriophage-based therapies for antibiotic resistant infections.
Subscribe to our email newsletter
Under the exclusive channel collaboration (ECC), AmpliPhi received an exclusive worldwide license to use Intrexon’s technology for the standardized production of wild type phages and for the design and production of genetically modified bacteriophages.
The deal gives AmpliPhi the unilateral right to terminate the ECC after 90 days’ notice at any time.
AmpliPhi provided written notice to Intrexon after securing approval from its board of directors to cancel the ECC.
AmpliPhi Biosciences CEO Scott Salka said: "Terminating this exclusive collaboration with Intrexon allows us to take advantage of the rapid advancements being made in the field of synthetic biology and frees us to partner with best-in-class technologies for genetically modifying phages to further improve their ability to conquer pathogenic bacteria resistant to current antibiotics."
Intrexon has recently entered into two new ECCs with two startups backed by the Harvest Intrexon Enterprise Fund.
The companies will carry out new approaches for unmet needs in human health by using Intrexon technologies.
Relieve Genetics will focus on a breakthrough, non-opioid gene therapy approach for neuropathic pain, while Exotech Bio will use a novel exosome-based platform to deliver therapeutic RNA for the treatment of select cancer indications.
Under the terms of the ECC deals for both collaborations, Intrexon will receive a technology access fee in the form of equity amounting to 25% of each startup.
The company will also get reimbursement for all research and development costs, as well as potential milestones and backend economics in the form of royalties.